


PHARMACEUTICAL 2022

Vicapsys Life Sciences Inc. Rank 286 of 475





PHARMACEUTICAL 2022

Vicapsys Life Sciences Inc. Rank 286 of 475

The relative strengths and weaknesses of Vicapsys Life Sciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vicapsys Life Sciences Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 125% points. The greatest weakness of Vicapsys Life Sciences Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is -167%, being 109% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	223
Cost of Goods Sold	0
Intangible Assets	372
Liabilities, Current	716
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	283
Other Liabilities	0
Other Net Income	100
Property and Equipment	0
Research and Development	18
Revenues	0
Selling, General and Administrative Expense	36

Output Variable	Value in 1000 USD
Assets	594
Liabilities	716
Expenses	337
Stockholders Equity	-122
Net Income	-237
Comprehensive Net Income	-237
Economic Capital Ratio	-167%